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• A meta-analysis of 31 RCTs of psychotherapy for adults with IBS was conducted.
• Psychotherapy signiﬁcantly improved both mental health and daily functioning.
• Several therapy modalities were similarly effective for improving mental health.
• Cognitive behavior therapy was most effective at improving daily functioning.Abbreviations: GI, gastrointestinal; IBS, irritable bowel
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Available online 08 November 2016Previous meta-analyses have shown that psychotherapy improves gastrointestinal symptoms in adults with irri-
table bowel syndrome (IBS); however, the impact on functioning in daily activities is unknown. Meta-analysis
was used to estimate the effect of psychotherapy on mental health and daily functioning in adults with IBS. An
extensive literature search located 28 eligible randomized controlled trials (RCTs) providing outcome data for
mental health and 18RCTs providing data for daily functioning. Compared to amixed group of control conditions,
psychotherapy produced signiﬁcantly greater improvements tomental health (d=0.41) and daily functioning (
d=0.43). Cognitive behavior therapy (CBT)was evaluated in the largest number of trials (21 trials), followed by
hypnosis (4 trials), psychodynamic (3 trials), and relaxation (2 trials). The psychotherapeutic modalities were
comparablewith respect to their effect onmental health. CBT produced the greatest improvements to daily func-
tioning, and this effect was signiﬁcantly larger than that produced by relaxation therapy. These results have im-
portant clinical implications for treatment of adults with IBS.
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Irritable Bowel Syndrome (IBS) is a common and often debilitating
functional gastrointestinal disorder (FGID) characterized by abdominal
pain and altered bowel habits. Like other FGIDs, IBS is thought to result
from reciprocal interactions between biological, psychological, and so-
cial factors, and has no universally effective medical treatment (Van
Oudenhove et al., 2016). Individuals with IBS report difﬁculties with a
broad range of daily activities compared to healthy controls (Hungin
et al., 2003). A systematic review of eleven studies found that the aver-
age cost of IBS to an individual's productivity ranges from $335 to $748
per year, with the total annual indirect cost estimated to be $205million
in the United States (Inadomi et al., 2003). This sizable impact of IBS on
daily functioning likely results not only fromgastrointestinal discomfort
but also from emotional distress (Bass, 2009). Psychological disorders
affect 50% to 94% of IBS patients (Lydiard, 2001; Whitehead et al.,
2002), and number of psychiatric diagnoses has been shown to predict
both degree of physical role limitations and number of days of restricted
activity 15months later. The degree of distresswas so great in one sam-
ple of tertiary care patients that 38% reported seriously contemplating
suicide as a result of their symptoms (Miller et al., 2004).
The lack of satisfactory medical treatment for IBS has led to the de-
velopment of a variety of psychological therapies. The rationale for
such therapies is grounded in the biopsychosocial model described by
Engel (Engel, 1980; Engel, 1977) and applied to FGIDs by Drossman
and colleagues (Drossman, 1998; Halpert & Drossman, 2005; Tanaka
et al., 2011). As it applies to IBS, this model states that thoughts, emo-
tions, and behaviors are bidirectionally related to gut physiology and
symptom manifestations. The model delineates several pathways
through which psychological factors may affect clinical outcomes (e.g.,
gastrointestinal symptoms, emotional wellbeing, and daily functioning)
in IBS.
Although several meta-analyses have evaluated the effect of psycho-
logical therapies on gastrointestinal symptoms in IBS (Ford et al., 2014;
Ford et al., 2009; Lackner et al., 2004; Laird et al., 2016), effects on other
important patient-reported outcomes remain largely unexamined. Spe-
ciﬁcally, no meta-analysis to date has investigated the effect of psycho-
therapies on functioning in daily activities, and only one meta-analysis
(publishedmore than a decade ago) has evaluated the effect of psycho-
therapies on mental health among individuals with IBS (Lackner et al.,
2004). Furthermore, nometa-analysis to date has investigated whether
therapeutic modality moderates these effects. Our previous meta-anal-
ysis reported that cognitive behavior therapy (CBT),1 relaxation thera-
py, and hypnosis therapy were similar in the magnitudes of their
effects on gastrointestinal symptoms (Laird et al., 2016); however,1 Despite its name, cognitive therapy is a cognitive behavioral intervention that often
incorporates behavioral strategies in the service of testing beliefs. Therefore we included
interventions labeled “cognitive therapy”within the larger category of “cognitive behavior
therapy”.whether these therapeutic modalities are comparable in their effects
onmental health and functioning is unknown. Because CBT ismore like-
ly to promote behavior change, it is possible that CBT will be associated
with greater improvements to functioning compared to other therapeu-
tic modalities.
Whether delivery method (online vs. in-person) or format of thera-
py (group vs. individual) moderate improvements tomental health and
daily functioning is another important question to explore, as this may
promote more effective or efﬁcient delivery of psychotherapy in this
population. Our previous meta-analysis reported that therapies deliv-
ered online were no less effective for reducing gastrointestinal symp-
toms than therapies delivered in person (Laird et al., 2016). This could
be good news for individuals living in geographically remote areas;
however, whether online therapies are as effective at improvingmental
health and daily functioning is unknown. Similarly, our previous meta-
analysis found that format of therapy (group vs. individual) did not sig-
niﬁcantly moderate the efﬁcacy of psychotherapy for improving gastro-
intestinal symptoms. If therapy delivered in a group format is as
effective as individual therapy for improving mental health and daily
functioning, this could be a cost-effective method of delivery.
How the dose of therapy is related to therapeutic outcomes is anoth-
er important question. A recent meta-regression of psychotherapy for
depression found thatmore sessions, greater total contact time between
therapist and patient, and greater number of sessions per week each
correlated with greater symptom improvement (Cuijpers et al., 2013).
However, these authors also found that a longer duration of therapy in
weeks was associated with less reduction of depressive symptoms. In
our previous meta-analysis, the effect of psychotherapy on gastrointes-
tinal symptoms was not signiﬁcantly moderated by any of the dosage
variables coded (number of sessions, session duration, therapy duration
in weeks, session frequency (Laird et al., 2016)). What effect such dos-
age characteristics have on improvements to mental health and daily
functioning in IBS is unknown.
Conclusions about the efﬁcacy of psychotherapy for IBS also may be
premature without adequate consideration of the type of control condi-
tion used. Unlike medication trials, in which placebo controls are the
gold standard, control conditions utilized in psychotherapy trials vary
widely (Huang et al., 2015). In our previous meta-analysis, gastrointes-
tinal symptom improvement was similar for trials using active ðd =
0.66) vs. non-active controls (d=0.68) (Laird et al., 2016). How control
condition type inﬂuences improvements to mental health and daily
functioning has yet to be investigated. Country in which the study was
conducted was another moderator of interest. In our previous analysis,
we found that studies conducted in Sweden produced signiﬁcantly
greater reductions in gastrointestinal symptoms compared to studies
conducted in the US and the UK (Laird et al., 2016). Of the ﬁve Swedish
trials included, the two providing exposure-based CBT had especially
large effect sizes and likely at least partially account for the greater av-
erage effect size found in Swedish trials. Whether Swedish studies also
demonstrate a greater improvement to mental health and daily func-
tioning is unknown.
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with larger differential effects will be useful information to clinicians,
researchers, and patients because it will help identify which individuals
aremost likely to beneﬁt from psychotherapy. IBS is two-to-three times
more common in women compared to men (Drossman et al., 1993;
Longstreth & Wolde-Tsadik, 1993), and among individuals with IBS,
women may exhibit higher degrees of psychological distress (Fock et
al., 2001; Corney & Stanton, 1990). Although the reason for this is not
entirely clear, gender role socialization likely plays some part (Chang
et al., 2006). However, sex did not signiﬁcantly moderate the efﬁcacy
of psychotherapy for improving gastrointestinal symptoms in our previ-
ous meta-analysis (Laird et al., 2016). The current analysis is the ﬁrst to
assess whether sex moderates the effect of psychotherapy on mental
health and daily functioning in adults with IBS.
The primary aims of this review were to 1) examine the efﬁcacy of
psychotherapy for improving mental health and daily functioning, and
2) investigate whether efﬁcacy is moderated by therapeutic modality
(i.e., CBT, hypnosis, psychodynamic, and relaxation therapy). Our sec-
ondary aimwas to explore additional potentialmoderators of treatment
effects. We evaluated several characteristics of the therapy as potential
moderators: delivery method (online, in-person), format (group, indi-
vidual), and dose (number of sessions, session duration, therapy dura-
tion in weeks, session frequency). We also evaluated trial
characteristics: type of control condition (active, non-active) and coun-
try in which the trial was conducted. Finally, we evaluated the percent
of female participants as a potential moderator of treatment effects. As
in our previous meta-analysis (Laird et al., 2016), in order to synthesize
the highest quality of research evidence available, we made the a priori
decision to include only randomized controlled trials.
2. Methods
This studywas conducted in accordancewith the PRISMA statement,
which provides a detailed guideline of preferred reporting style for sys-
tematic reviews and meta-analyses (Liberati et al., 2009; Moher et al.,
2009).
2.1. Search strategy
We searched PubMed, PsycINFO, Science Direct, and ProQuest Dis-
sertations and Theses throughAugust 15th 2015.We used terms related
to IBS, psychotherapy, and controlled trials (see Appendix A for full
search details).
2.2. Selection criteria
Eligible studies were (a) randomized controlled trials (RCTs) of (b)
psychological intervention(s) for (c) individuals with IBS aged
18 years or older that (d) assessed mental health or daily functioning
pre- and post-treatment using a continuousmeasure andwere (e)writ-
ten in English. To be as conservative and as consistent in the application
of our eligibility criteria as possible, trials that used quasi-random
methods of allocation assignment (e.g., assignment based on order of
entry into the trial or social security number) were excluded to the ex-
tent that this could be determined (Hunt et al., 2009; Mahvi-Shirazi et
al., 2012; Lowen et al., 2013; van Dulmen et al., 1996; Siegel, 2003).
Cluster randomization was considered acceptable for trials evaluating
therapies administered in a group format. We judged an intervention
to be psychological if it was based on a psychological model or frame-
work. Studies in which the only psychological intervention was a sup-
port group were not included due to the frequent use of support
groups as a control condition.
Eligible control conditions were supportive therapy or support
groups, education controls, “sham” treatments (for trials of biofeedback
and hypnosis), online discussion forums, enhanced medical care (de-
ﬁned as any medical care not received by the intervention group),‘treatment as usual’ (TAU), symptom monitoring, and wait-list. En-
hanced medical care was only eligible to serve as a control condition if
no antidepressant was administered to all participants.
Published and unpublished trials were eligible, including refereed
journals, non-refereed journals, and dissertations. Although some re-
searchers have argued that it is legitimate to exclude unpublished trials
frommeta-analyses (Weisz et al., 1995), it is not clear that published tri-
als are always of high quality, nor that unpublished trials are always of
poor quality. To limit publication bias, we therefore attempted to iden-
tify all relevant trials, including those in gray/unpublished literature, fol-
lowing recent recommendations (Borenstein et al., 2011). Details of our
screening and coding procedures are provided in Appendix B.
2.3. Outcome assessment
Onlymental health outcome data using validatedmeasures were el-
igible for inclusion. Because validated measures of daily functioning
have only recently become available, data fromnon-validated question-
naires were permitted for this outcome.
Mental health outcomes (in order of preference, based on availabil-
ity) were 1) an overall index of mental health, 2) frequency or severity
of anxiety symptoms, and 3) frequency or severity of depressive symp-
toms. Our decision to prioritize measures of anxiety over those of de-
pression was informed by evidence that symptoms of anxiety may be
more prevalent than depressive symptoms in individuals with IBS
(Janssens et al., 2015; Mykletun et al., 2010). Within a fear-avoidance
framework (Lethem et al., 1983; Vlaeyen & Linton, 2000), even subclin-
ical levels of anxiety are thought to inﬂuence the course of IBS – a hy-
pothesis supported by longitudinal research (El-Serag et al., 2004). If
prevention or early treatment is the goal, it may be especially important
that psychological interventions for individuals with IBS reduce symp-
toms of anxiety.We anticipated that our approachwould be a conserva-
tive one, as a previous meta-analysis showed slightly larger mean
effects of psychological therapies on depressive symptoms compared
to symptoms of anxiety (Lackner et al., 2004). Usablemental health out-
come data were provided in 28 trials. We also calculated effect sizes for
anxiety and depressive symptoms separately to test for potential differ-
ences in the efﬁcacy of psychotherapy for reducing these psychological
symptoms in adults with IBS.
We operationalized daily functioning as the degree towhich an indi-
vidual can engage in daily activities regardless of any physical symp-
toms that may or may not be present. Daily functioning outcomes (in
order of preference, based on availability) were 1) an overall measure
of life functioning, activity impairment (reverse scored), or disability
(reverse scored) (Leon et al., 1997; Mundt et al., 2002), 2) role physical
functioning (ability to work and engage in other daily activities regard-
less of physical health (Ware et al., 1993; Drossman et al., 2000; Patrick
et al., 1998)), and 3) social functioning (ability to participate in social ac-
tivities regardless of physical health (Lahmann et al., 2010)). Eighteen
trials provided usable outcome data for daily functioning.
When a trial reported outcome data using multiple measures of a
particular outcome (for example, both the SF-36 Mental Health scale
and the SCL-90 Global Severity Index as indicators of mental health),
data were extracted for the measure that was most frequently used
for that outcome within the remaining sample of eligible studies. The
SF-36 Mental Health scale was the most frequently used measure of
mental health and the SF-36Role Physical scalewas themost frequently
usedmeasure of daily functioning. Self-reported outcomeswere used in
all trials except two that provided only physician-reported measures
(Lahmann et al., 2010; Svedlund et al., 1983).
2.4. Data extraction
Datawere extracted as intent-to-treat (ITT; i.e., analyzed as random-
ized, using all available follow-up data) when possible. Data were ex-
tracted with imputation of missing data when possible, if the method
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likelihood, expectation maximization, or last observation carried for-
ward if none of the former were available).
We coded several aspects of the included studies, including the fol-
lowing intervention characteristics: 1) therapeutic modality (CBT, psy-
chodynamic, hypnosis, and relaxation therapy); 2) delivery method
(online, in-person, telephone, or self-help); 3) format (group, individu-
al); and 4) dose (number of in-person sessions, average session dura-
tion, therapy duration in weeks, and session frequency). We assessed
the following trial characteristics: 1) type of control condition (active
vs. non-active), and 2) country in which the trial took place. Control
groups were classiﬁed as either active or non-active. Active controls in-
cluded supportive therapy, online discussion forums, education, “sham”
treatments, enhanced medical care, and TAU. Non-active controls in-
cluded wait-list or symptom monitoring. Controls containing both ac-
tive and non-active components were coded as active (Ljótsson et al.,
2011; Ljótsson et al., 2010). Finally, we assessed the following partici-
pant characteristics: 1) diagnostic criteria (Rome criteria, Manning
criteria, physician diagnosed); 2) sex ratio of participants (percent fe-
male); 3) racial diversity of participants (percent Caucasian); 4) mean
durationof gastrointestinal symptoms in years (or years since diagnosis,
if the former was not available).
2.5. Missing data
Authors were contacted when reports provided insufﬁcient data for
effect size computation and when selective reporting was suspected.
When a trial included both eligible and ineligible participants
(Schröder et al., 2012), datawere requested for those participantsmeet-
ing our inclusion criteria.
2.6. Data synthesis and statistical analysis
Standardized mean differences (SMDs) were computed as a mea-
sure of effect size. The SMDs were computed as the difference between
the two groups' mean change scores divided by their pooled standard
deviation.2 To calculate pooled mean effect sizes, we used the Compre-
hensive Meta-Analysis software (version 3.3.070). Effect sizes were
weighted by the inverse of their variances. Following recommendations
that random effects-models be used when different measures are used
across trials (Higgins et al., 2003), we made an a priori decision to use
this model. A random-effects model assumes measurement error be-
yond subject sampling error is randomly distributed across studies. In
random effects moderator analysis, the between-study variance (tau-
squared) is not assumed to be the same for all subgroups. This value is
computed separately for the two subgroups and not pooled across sub-
groups. In addition to the SMD, 95% conﬁdence intervals were calculat-
ed; conﬁdence intervals not including zerowere considered statistically
signiﬁcant.
Six trials [ﬁve providingdata formental health [49–53] and four pro-
viding data for daily functioning (Boyce et al., 2003; Deechakawan et al.,
2013; Heitkemper et al., 2004; Craske et al., 2011)] had two psycholog-
ical treatments that were compared to the same control condition.
Given that this standard random-effects meta-analysis model assumes
uncorrelated error terms, we used a set of selection criteria to ensure
the statistical independence of effect sizes included in each synthesis.
Namely, to avoid statistical dependencies in the data, we included out-
come data for only the treatment arm hypothesized by the authors to
be most effective (due to either greater number of sessions, in-person2 The variance of this effect size requires information on the pretest-posttest correla-
tion, which was rarely reported by trial authors. We therefore calculated the average of
all provided pretest-posttest correlations, and used this value (0.629 for mental health
and 0.614 for functioning) when no pretest-posttest correlation was provided.delivery method, or particular format/treatment modality) in any
given analysis. When a trial hadmore than one control arm, we only in-
cluded outcome data for the less active control in any given analysis.
This was to facilitate comparisons to past meta-analyses in which the
majority of included studies had non-active control arms (Lackner et
al., 2004).We then conducted sensitivity analyses to determine the im-
pact of these two decisions on effect size estimates.
We tested whether there were genuine differences underlying the
differences in effect sizes between studies (heterogeneity) or whether
these were likely a result of chance (homogeneity) (Higgins et al.,
2003). As an indicator of homogeneity, we calculated the Q-statistic (a
measure of weighted squared deviations around the mean). A signiﬁ-
cant Q rejects the null hypothesis of homogeneity and indicates that
the observed variability in effect sizes is unlikely to be a result of sub-
ject-level sampling error alone. We also calculated the between-studies
variance (τ2) and the ratio of true heterogeneity to total observed vari-
ation (I2).
2.7. Assessment of publication bias and risk of study bias
Publication bias occurs when studies with large effects are more
likely to be published and therefore aremore easily located for inclusion
in meta-analyses. Publication bias is more likely to affect small trials;
thus, plots of trial effect size by degree of precision (e.g., variability or
sample size) are usually asymmetrical (with a deﬁcit of small studies
with weak effects) in the presence of publication bias (Sterne & Egger,
2001). We conducted two statistical tests to determine whether study
effect size was signiﬁcantly related to study precision – the rank corre-
lation test (which uses Kendall's rank correlation coefﬁcient) and
Egger's test (which regresses the effect size on the standard error of
the effect size). A p-value of b0.05 indicates a signiﬁcant association be-
tween the effect size and precision, and therefore signiﬁes the possibil-
ity of publication bias.
We used the risk of bias assessment tool developed by the Cochrane
Collaboration for RCTs (Higgins & Altman, 2008) to assess the following
possible sources of bias in included trials: 1) adequate generation of al-
location sequence; 2) concealment of allocation to conditions; 3)
blinding of participants and personnel, 4) handling of incomplete out-
come data, and 5) selective outcome reporting. The tool allows for
‘high’, ‘low’, and ‘unclear’ risk of bias ratings. Appendix C describes our
criteria for assessing risk of bias.
3. Results
A study ﬂow diagram (Fig. 1) shows the steps of identifying eligible
trials. Of the 1162 records identiﬁed in the search, 31 unique trials were
determined to be eligible for the meta-analysis and are presented in
Table 1. Most reports included only one trial, but two reports (Lindfors
et al., 2012; Blanchard et al., 1992) presented data on two studies and
are therefore listed in two rows. Trials that contained multiple eligible
psychotherapy conditions also span multiple rows.
3.1. Main effects
Mean effects of psychological therapies on mental health and daily
functioning compared to a mixed group of control conditions using
the ﬁrst post-treatment assessment are shown in Figs. 2 and 3, respec-
tively. The range of theﬁrst post-treatment assessmentwas 0–5months
post-treatment for mental health and 0–2 months post-treatment for
daily functioning. Positivemean effect sizes indicate that the designated
treatment group demonstrated greater average improvement com-
pared to the control group; negative mean effect sizes indicate the re-
verse. Compared to a mixed group of (active and non-active) control
conditions, psychological therapies were effective at improving both
mental health (d = 0.41, p b 0.001, 95%CI [0.29,0.54]) and daily
Records identified through
database search
(n = 831)
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n Records identified through
other sources
(n = 507)
Records after duplicates removed
(n = 1162)
Records screened
(n = 1162)
Abstracts excluded for
clear ineligibility
(n = 1026)
Full-text articles
assessed for eligibility
(n = 136)
Full-text articles
excluded:
Ineligible intervention
(n =7)
Ineligible population
(n = 12)
Ineligible design
(n =19)
No eligible outcome
(n = 17)
Redundant data from
another report
(n = 50)
Studies included in
meta-analysis
(n = 31)
Fig. 1. Flow diagram summarizing trial identiﬁcation and selection.
146 K.T. Laird et al. / Clinical Psychology Review 51 (2017) 142–152functioning (d=0.43, p b 0.001, 95%CI [0.30,0.55]).3 There was a non-
signiﬁcant degree of heterogeneity in the effect of psychotherapy on
mental health (Q=37.78, p=0.081, I2 = 28.54) and daily functioning
(Q= 20.87, p= 0.232, I2 = 18.54).3.1.1. Impact of publication bias and study risk of bias
There was no evidence of publication bias for the outcome ofmental
health, as indicated by Egger's test (b=−0.16, p=0.833) and the rank
correlation test (τ=−0.11, p= 0.418). There was also no evidence of
publication bias for the outcome of daily functioning, as indicated by
Egger's test (b = −0.71, p = 0.590) and the rank correlation test
(τ=−0.13, p=0.449). Funnel plots of main effects for both outcomes
are provided in Appendix D. Thus, there was no evidence of signiﬁcant
publication or small study bias in the meta-analysis results.
Table 2 presents the risk of bias ratings. The number of trialsmeeting
criteria for low risk of bias due to (1) allocation sequence, (2) conceal-
ment of allocation sequence, (3) blinding, (4) incomplete outcome
data, and (5) selective reportingwere: 17, 15, 2, 17, and 30, respectively.
In a series of pre-speciﬁed analyses,we investigatedwhether risk of bias
ratings were associated with effect size. Risk of bias categories contain-
ing fewer than two studies were omitted from the analyses. No risk of
bias domain was signiﬁcantly associated with the magnitude of the ef-
fect of psychotherapy on mental health or daily functioning. Thus, the
overall mean effects were robust to the quality or risk of bias of the in-
cluded studies.3 Sensitivity analyses were conducted in which effect size data from the most active
control arms and the intervention arms hypothesized by the authors to be least effective
were selected. As expected, using these data, average effects were only slightly smaller
for mental health (d = 0.39, p b 0.001, 95%CI [0.26,0.52]) and daily functioning (d
= 0.38, p b 0.001, 95%CI [0.24,0.52]).3.2. Moderator analyses
3.2.1. Intervention characteristics
3.2.1.1. Therapeutic modality. Of the trials providing outcome data for
mental health, CBT was the most frequent treatment modality (19 tri-
als), followedbyhypnosis (3 trials) psychodynamic (3 trials), and relax-
ation (2 trials). Similarly, of the trials providing outcome data for daily
functioning, CBT was the most frequent treatment modality (9 trials),
followed by hypnosis (4 trials) psychodynamic (2 trials), and relaxation
(2 trials). These therapy types were evaluated to determine their rela-
tive efﬁcacy compared to mixed control conditions. The therapy types
were comparable in the magnitude of their effects on mental health
(Qb=1.85, p = 0.603), but less so with respect to their effects on
daily functioning (CBT d=0.55, pb0.001,95%CI [0.38, 0.71]; psychody-
namic d ¼ 0:53; p b 0.001, 95%CI [0.26,0.79]; hypnosis d = 0.29, p =
0.013, 95% CI [0.06, 0.53]); relaxation d = −0.09, p=0.670 ,95%CI
[−0.48, 0.31];Qb=10.35, p=0.016). Speciﬁcally, CBT produced signif-
icantly greater improvements to daily functioning compared to relaxa-
tion therapy (Qb=8.44, p = 0.004). Psychodynamic therapies also
had signiﬁcantly larger effects on daily functioning than relaxation ther-
apy (Qb=6.35, p= 0.012). CBT was not signiﬁcantly more effective at
improving daily functioning compared to hypnosis, although this effect
approached signiﬁcance (Qb=3.069 ,p=0.080). No other effect size
comparisons between therapy types approached signiﬁcance. Average
effects on daily functioning by therapy type are presented in Fig. 4.3.2.1.2. Online vs. In-person deliverymethod.Wewere unable to compare
the effects on mental health of therapies delivered online vs. in-person
because only one online trial provided outcome data for mental health
(Ljótsson et al., 2010). Improvements to daily functioning were
Table 1
Descriptive statistics for characteristics of included studies.
First author Year Country N Race Sex Recruitment Years Criteria Therapy Delivery Format Sessions
Blanchard - S1 1992 US 20 77 Local; clinic 16 Phys+ Cognitive In person Individual 12
Blanchard - S2 1992 US 76 66 Local; clinic 13 Phys+ Cognitive In person Individual 12
Boyce 2003 AU 69 81 Local; clinic RI Cognitive In person Individual 8
Boyce " " " " " " " " Relaxation " " "
Corney 1991 UK 42 74 Clinic Phys+ Behavioral In person Individual 10.5a
Craske 2011 US 69 72 74 Local; clinic RII; phys+ Cognitive In person Individual 10
Creed 2003 UK 171 98 79 Clinic RI Dynamic In person Individual 8
Deechakawan 2013 US 118 91 86 Local; clinic RII; phys Cognitive In person Individual 9
Deechakawan " " " " " " " " " In person; phone " 9
Gaylord 2011 US 75 76 100 Online; local; clinic RII; phys Cognitive In person Group 9
Greene 1994 US 20 100 75 Local; clinic 15 Phys Cognitive In person Individual 10
Guthrie 1991 UK 102 77 Clinic 4 Phys+ Dynamic In person Individual 7
Haghayegh 2010 Iran 32 50 Clinic RII Cognitive In person Individual 8
Heitkemper 2004 US 95 87 100 Local; clinic RI; phys Cognitive In person Individual 8
Heitkemper “ “ “ “ “ “ “ “ “ “ 1
Heymann-Monnikes 2000 Germany 26 88 Clinic RI Cognitive In person Individual 10
Labus 2013 US 69 84 72 Clinic RII; phys+ Cognitive In person Group 5
Lackner 2008 US 50 95 86 Local; clinic 17 RII; phys+ Cognitive In person Individual 10
Lackner “ “ “ “ “ “ “ “ “ “ “ 4
Lahmann 2010 Germany 80 66 Clinic RII; phys+ relaxation In person Group 10
Lindfors - S1 2012 Sweden 90 79 Clinic RII; phys+ Hypnosis In person Individual 12
Lindfors - S2 2012 Sweden 48 81 Clinic RII Hypnosis In person Individual 12
Ljotsson 2011 Sweden 61 74 Clinic 12 RIII Cognitive Online Individual 0
Ljotsson 2010 Sweden 86 85 Online; local; clinic RIII; phys Cognitive Online Individual 0
Moser 2013 Austria 12 79 Clinic RIII Hypnosis In person Group 10
Moss-Morris 2010 AU 63 90 73 Clinic RI or RII; phys+ Cognitive In Person; phone Individual 3
Payne 1995 US 34 85 Not reported b1 RI; phys+ Cognitive In person Individual 10
Roberts 2006 UK 73 85 Clinic phys+ Hypnosis In person Individual 5
Sanders 2007 US 28 100 78 Local; clinic 16 RII; phys Cognitive Self-help Individual 0
Schroeder 2012 Denmark 37 79 Clinic 8 Phys+ Cognitive In person Group 9
Shinozaki 2010 Japan 101 52 Not reported Phys+ Relaxation In person Individual 8
Svedlund 1983 Sweden 22 69 Clinic 13 RII Dynamic In person Individual 10
Tkachuk 2003 US 44 96 Clinic 9 RII; phys+ Cognitive In person Group 10
Vollmer 1998 US 21 78 Local; clinic 13 RI Cognitive In person Group 10
Vollmer " " " " " " " " Cognitive " Individual "
Zernicke 2013 Canada 25 90 Local Phys Cognitive In person Group 9
Note: S1= Study 1; S2= Study 2. Country denotes the country in which the study was conducted: AU=Australia. N denotes the number of participants who completed baseline study
measures. Race denotes the percentage of the post-treatment sample that was Caucasian. Sex denotes the percent of the post-treatment sample that was female (if not available, baseline
demographic datawere used). Recruitment denotes themethod used to recruit participants: Local= local advertisement; clinic= in clinic or throughphysician referral. Years denotes the
average number of years since diagnosis or symptomonset. Sessions denotes the number of in person sessions offered to participants in the intervention group. Therapy denotes the active
intervention evaluated. Criteria denotes the diagnostic criteria used to deﬁne IBS: RI, RII, and RIII denote Rome I–III criteria, respectively; phys=physician diagnosed; phys+=physician
diagnosed including a physical exam.
a The treatment protocol for this study did not specify a standard number of sessions; participants were “mostly seen at weekly intervals for 6–15 one-hourly sessions”.
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95% CI [0.44, 1.16]) compared to those delivered in-person (d = 0.39,
p b 0.001, 95% CI [0.27, 0.51]; Qb = 4.62, p = 0.032), although only
two online therapy trials were included in this analysis (Ljótsson et al.,
2011; Ljótsson et al., 2010).
3.2.1.3. Individual vs. group format. We tested whether effect sizes dif-
fered for therapies administered individually vs. in a group. For this
analysis, as well as for all analyses investigating therapy “dose” (num-
ber, duration, and frequency of sessions), interventions that were pri-
marily online or self-help were excluded (Ljótsson et al., 2011;
Ljótsson et al., 2010; Moss-Morris et al., 2010; Sanders et al., 2007).
There was no difference in the effect of therapies delivered in a group
vs. individual format for mental health (Qb = 0.03, p= 0.863) or daily
functioning Qb = 0.22, p= 0.638).
3.2.1.4. Number of sessions.We tested whether a greater number of talk
therapy sessions (including in-person sessions and sessions conducted
over the phone) was associated with greater improvements to mental
health or daily functioning (primarily online or self-help interventions
excluded). Among therapies whose primary delivery method was talk
therapy, the number of sessions ranged from ﬁve to twelve. A meta-re-
gression revealed no signiﬁcant relation between number of sessions
and effect onmental health (b=−0.07, p=0.073) or daily functioning
(b=−0.06, p= 0.090).3.2.1.5. Therapy duration. We tested whether the average duration of
sessions inminutes or total duration of therapy inweekswas associated
with greater improvements to mental health or daily functioning (pri-
marily online or self-help interventions excluded). Session duration
ranged from 30 min to 210 min and had no signiﬁcant effect on im-
provements to mental health (b b−0.01, p= 0.103) or daily function-
ing (b b 0.01, p= 0.790). Therapy duration ranged from ﬁve to sixteen
weeks, and had a very small but signiﬁcant negative effect on mental
health (b = −0.06, p = 0.019) and no effect on daily functioning
(b= 0.03, p= 0.223). However, once the single trial with the longest
therapy duration (Schröder et al., 2012)was removed, the effect of ther-
apy duration on mental health was no longer signiﬁcant (b =−0.03,
p = 0.266). The next longest duration of therapy of any trial was
13 weeks (Deechakawan et al., 2013).
3.2.1.6. Frequency of sessions.We investigated whether session frequen-
cy (which ranged from 0.6 (Schröder et al., 2012) to 2.0 (Lahmann et al.,
2010) sessions per week) was signiﬁcantly associated with effects on
mental health and daily functioning. Again, interventions that were pri-
marily online or self-help were excluded from these analyses. Session
frequencywas not signiﬁcantly associatedwith improvement tomental
health (b=0.25, p=0.201). Reduced session frequencywas associated
with greater improvement to daily functioning (b=−0.44, p=0.014).
However, when the single trial with the greatest weekly session fre-
quency was removed (Lahmann et al., 2010), this effect was no longer
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Schröder et al., 2012 -0.508
Boyce et al., 2003 -0.156
Lindfors et al., 2012-study 2 -0.052
Sanders et al., 2007 -0.010
Moss-Morris et al., 2010 0.027
Corney et al., 1991 0.097
Vollmer & Blanchard, 1998 0.164
Zernicke et al., 2013 0.211
Svedlund et al., 1983 0.233
Gaylord et al., 2011 0.273
Lindfors et al., 2012-study 1 0.334
Blanchard et al., 1992-study 1 0.363
Blanchard et al., 1992-study 2 0.411
Ljotsson et al., 2010 0.428
Moser et al., 2013 0.468
Greene & Blanchard, 1994 0.531
Guthrie et al., 1991 0.533
Lackner et al., 2008 0.535
Creed et al., 2003 0.536
Tkachuk et al., 2003 0.558
Haghayegh et al., 2010 0.559
Deechakawan et al., 2013 0.582
Lahmann et al., 2010 0.632
Shinozaki et al., 2010 0.645
Heitkemper et al., 2004 0.690
Heymann-Monnikes et al., 2000 0.865
Labus et al., 2013 1.059
Payne & Blanchard, 1995 1.678
0.412Mean Effect Size
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0.258
0.313
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0.264
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0.232
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Fig. 2.Mean effects of psychological therapies on mental health symptoms compared to a mixed group of control conditions at the ﬁrst post-treatment assessment.
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frequency of any trial was 1.125 sessions per week (Gaylord et al.,
2011).
3.2.2. Trial characteristics
3.2.2.1. Active vs. non-active control condition. Degree of improvement to
mental health among trials using active controls ( d = 0.38,
pb0.001,95%CI [0.24,0.52]) compared to those using non-active con-
trols (d=0.49, pb0.001,95%CI [0.24,0.74])was not signiﬁcantly differ-
ent (Qb = 0.55, p= 0.458). Similarly, degree of improvement to dailyStd diff
in means
Standard
error
Lahmann et al., 2010 -0.088 0.227
Shinozaki et al., 2010 -0.075 0.437
Lindfors et al., 2012-study 1 0.072 0.211
Lindfors et al., 2012-study 2 0.149 0.289
Craske et al.,2011 0.190 0.274
Boyce et al., 2003 0.261 0.323
Schröder et al., 2012 0.262 0.335
Roberts et al., 2006 0.361 0.248
Creed et al., 2003 0.430 0.172
Corney et al., 1991 0.462 0.317
Heitkemper et al., 2004 0.520 0.228
Gaylord et al., 2011 0.534 0.235
Deechakawan et al., 2013 0.546 0.194
Moser et al., 2013 0.558 0.216
Ljotsson et al., 2010 0.676 0.229
Guthrie et al., 1991 0.680 0.219
Moss-Morris et al., 2010 0.790 0.268
Ljotsson et al., 2011 1.016 0.301
0.427Mean Effect Size 0.065
p-Value
0.696
0.863
0.733
0.608
0.488
0.418
0.434
0.146
0.012
0.144
0.022
0.023
0.005
0.010
0.003
0.002
0.003
0.001
0.000
-2.00
Fig. 3.Mean effects of psychological therapies on daily functioning compared tofunctioning among trials using active controls ( d = 0.42,
pb0.001,95%CI [0.29, 0.56]) compared to those using non-active con-
trols (d=0.45, pb0.090,95% CI [−0.07, 0.97]) was not signiﬁcantly dif-
ferent (Q= 0.01, p= 0.921).
3.2.2.2. Country.Most trials providingmental health outcome data were
conducted in the US (12 trials), followed by Sweden (4 trials) and the
UK (3 trials). These countries did not signiﬁcantly differ in the magni-
tude of their effects on mental health (Q= 4.50, p= 0.105). An equal
number of trials providing outcomedata for daily functioningwere con-
ducted in the US, Sweden, and the UK (4 trials each). There was noFavors control Favors treatment
-1.00 0.00 1.00 2.00
a mixed group of control conditions at the ﬁrst post-treatment assessment.
Table 2
Risk of bias ratings for all studies.
First author Year Sequence generation Allocation concealment Blinding % Dropout ITT Attrition Selective reporting
Blanchard - S1 1992 Unclear Unclear High (Unclear) 0.00 Y Low Low
Blanchard - S2 1992 Unclear Unclear High (Low) 20.00 N Unclear Low
Boyce 2003 Low Low High 49.52 N High Low
Corney 1991 Unclear Unclear (High) 2.38 Y Low Low
Craske 2011 Low Low (Unclear) 21.81 Y Unclear Low
Creed 2003 Low Low High 10.53 Y Low Low
Deechakawan 2013 Low Low High 18.62 Y Low Low
Gaylord 2011 Low Low (Unclear) 31.96 Y Unclear High
Greene 1994 Unclear Unclear High 10.00 N Unclear Low
Guthrie 1991 Unclear Unclear High 12.75 N Unclear Low
Haghayegh 2010 Unclear Unclear (High) 25.00 N High Low
Heitkemper 2004 Low Low High 8.33 Y Low Low
Heymann-Monnikes 2000 Low Unclear Unclear 7.69 N Unclear Low
Labus 2013 Unclear High High 0.00 Y Low Low
Lackner 2008 Low Low High 20.00 Y Low Low
Lahmann 2010 Unclear Unclear (High) 2.50 Y Low Low
Lindfors - S1 2012 Low Low (High) 3.33 Y Low Low
Lindfors - S2 2012 Low Low High 6.25 Y Low Low
Ljotsson 2011 Low Low (High) 18.03 Y Low Low
Ljotsson 2010 Low Low (High) 5.81 N Unclear Low
Moser 2013 Low Low (Unclear) 4.87 Y Low Low
Moss-Morris 2010 Low Low (High) 6.25 Y Low Low
Payne 1995 Unclear Unclear High (Low) 8.33 N Unclear Low
Roberts 2006 Unclear Unclear High 18.00 Y Low Low
Sanders 2007 Low Low High 42.86 N High Low
Schröder 2012 Low Low (High) 16.28 Y Low Low
Shinozaki 2010 Unclear Unclear (High) 0.00 Y Low Low
Svedlund 1983 Unclear Unclear (High) 1.98 N Low Low
Tkachuk 2003 Unclear Unclear (High) 34.88 N High Low
Vollmer 1998 Unclear Unclear High 6.25 N Unclear Low
Zernicke 2013 Low Unclear High 33.33 Y Unclear Low
Possible ratings were low, high, or unclear risk of bias. Studies with two control groups were rated twice for risk of bias resulting from lack of blinding (ratings for active control groups
appear in parentheses). ITT indicates whether the analyses were intent-to-treat (analyzed as randomized). S1 = Study 1; S2 = Study 2.
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daily functioning (Q= 0.01, p= 0.995).
3.2.3. Participant characteristics
3.2.3.1. Sex.Meta-regression analysis revealed no relation between per-
centage of female participants degree of improvement to mental health
(b b 0.01, p= 0.943) or daily functioning (b b 0.01, p= 0.157). These
null ﬁndings should be interpreted with caution, however, as limitedStd diff
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Fig. 4.Mean effects of psychotherapy on davariability in this variable may have masked an effect. In all but one
trial that reported this variable, the majority of participants were
women (range: 50%–100%).
3.2.3.2. Other participant characteristics.Wewere unable to test whether
race or duration of gastrointestinal symptoms moderate the efﬁcacy of
psychotherapy onmental health or functioning because too few studies
reported these variables. Among studies that did report race, themajor-
ity of participants were Caucasian (range: 72%–100%).Favors control Favors treatment
-1.00 0.00 1.00 2.00
ily functioning, by treatment modality.
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To test whether effect size was signiﬁcantly moderated by length of
follow-up interval, we computed effect sizes separately for assessments
less than one month post-treatment, one-to-ﬁve months post-treat-
ment, and six-to-twelve months post-treatment. For mental health, ef-
fect sizes were similar at less than one month (d = 0.42, p b 0.001,
95% CI [0.30,0.55]), one-to-ﬁve months ( d = 0.39,
p b 0.001, 95%CI [0.22,0.56]) and six-to-twelve months post-treatment
(d=0.33, p=0.012, 95%CI [0.07,0.58]). Similarly, for daily functioning,
effect sizes were similar at less than one month (d = 0.43, p b 0.001,
95%CI [0.30,0.57]), one-to-ﬁve months (d = 0.49, p b 0.001, 95% CI
[0.24, 0.75]) and six-to-twelve months post-treatment (d = 0.42,
p b 0.001, 95% CI [0.23, 0.61]).
3.2.5. Type of mental health outcome
To explore potential differences in the efﬁcacy of psychotherapy for
reducing symptoms of anxiety vs. depression in IBS, we also estimated
effect sizes for anxiety and depression separately. An analysis including
data from 20 studies revealed a signiﬁcant effect of psychotherapy on
symptoms of anxiety (d= 0.37, p b 0.001, 95% CI [0.19, 0.55]). An anal-
ysis including data from 21 studies revealed a signiﬁcant effect of psy-
chotherapy on symptoms of depression ( d = 0.29,
p b 0.001, 95%CI [0.14,0.45]). There was a signiﬁcant degree of hetero-
geneity in the effect on both anxiety (Q=37.43, p=0.007, I2=49.24)
and depression (Q= 32.93, p= 0.034, I2 = 39.26).
4. Discussion
The psychological interventions included in this meta-analysis were
effective at improvingmental health and (with the exception of relaxa-
tion therapy) daily functioning in adults with IBS. CBT was evaluated in
the largest number of trials (21 trials), followed by hypnosis (4 trials),
psychodynamic (3 trials), and relaxation therapy (2 trials). CBT pro-
duced the greatest improvement to daily functioning. The magnitude
of this effect was signiﬁcantly greater than that of relaxation therapy,
whichdid not signiﬁcantly improve functioning in our sample of eligible
trials. There were no signiﬁcant differences between treatment modal-
itieswith respect tomental health. These ﬁndings should be interpreted
cautiously, however, given the small number of included studies using
each of these therapeutic modalities and hence our limited statistical
power to detect differences in effects across modalities. Our effect size
estimates largely replicate those by Lackner and colleagues for mental
health (Lackner et al., 2004) (being virtually identical for anxiety al-
though a little lower for depression) and go beyond to estimate the ef-
fect of psychotherapy on daily functioning.
The estimated effects of psychotherapy on mental health and func-
tioning were considerably lower than that recently calculated for gastro-
intestinal symptoms (Cohen's ds ranging from 0.69 to 0.76 depending on
the follow up interval) (Laird et al., 2016). As others have proposed, this
suggests that psychological therapies are currently more effective at
reducing somatic symptoms compared to psychological ones (Lackner
et al., 2004). Effects on mental health were the smallest of the three
outcomes (mental health, daily functioning, and gastrointestinal symp-
toms) assessed in this and our previous meta-analysis (Laird et al.,
2016). Future research should identify methods of increasing the efﬁcacy
of psychotherapy for improving mental health in IBS.
The currentmeta-analysis extended beyondother recentmeta-anal-
yses on this subject (Ford et al., 2014; Laird et al., 2016) to investigate
the efﬁcacy of psychological therapies on mental health and daily func-
tioning. Ameta-analysis of the effect of psychotherapy onmental health
in IBS has not been conducted in over a decade (Lackner et al., 2004),
and to our knowledge, no prior meta-analysis of the effect of psycho-
therapy on functioning has been conducted in this population. As others
have argued (Kazdin & Wilson, 1978), multiple criteria should be usedwhenever evaluating the efﬁcacy of psychotherapy. Mental health and
daily functioning are bidirectionally related to physical health out-
comes, and are important outcomes to assess when evaluating the efﬁ-
cacy of psychotherapy for individuals with IBS. Moreover, to the extent
that brain-gut interactions contribute to IBS, psychological processes
constitute an important target for therapeutic intervention.
The current study further extends previous work (Ford et al., 2014)
by allowing for inclusion of 1) continuous outcome data, 2) short-term
(less than seven day duration) therapies, and 3) trials with less than a
seven day follow-up post-treatment assessment. Finally, and perhaps
most relevant to intervention research, policy, and practice, this is the
ﬁrst meta-analysis to 1) directly compare the efﬁcacy of different treat-
ment modalities for improving mental health and functioning in IBS,
and 2) test for other treatment, control condition, participant, and trial
characteristics that might moderate the efﬁcacy of psychotherapy on
these outcomes.
While it is impossible to know what led to a relatively greater im-
provement in daily functioning in CBT compared to relaxation therapy,
the former ismore likely to encourage clients to confront uncomfortable
situations than the latter. Others have observed that CBT incorporates
enactive procedures like exposure (often, but not exclusively, in the
context of running “behavioral experiments” to test the accuracy of be-
liefs) and differs from themore purely behavioral interventionsmore in
terms of their proposed mechanisms (belief change vs extinction) than
the procedures they use (Olatunji et al., 2010). Exposure may more di-
rectly increase daily functioning compared to other therapeutic modal-
ities by giving individuals the opportunity to practice engaging in their
daily routines despite their physical symptoms. Exposure may also re-
duce hypervigilance to visceral sensations, a characteristic of IBS
thought to exacerbate symptoms (Craske et al., 2011; Naliboff et al.,
1997; Verne et al., 2001). A recent dismantling study of 309 adults
with IBS found that CBT with systematic exposure led to greater reduc-
tion in gastrointestinal symptoms relative to the same CBT protocol
without an exposure component (Ljótsson et al., 2014). Two other stud-
ies of exposure-based CBT conducted by the same research team pro-
duced the largest and fourth-largest effects of the 41 trials included in
our meta-analysis of the effect of psychotherapies on gastrointestinal
symptoms (Ljótsson et al., 2010; Ljótsson et al., 2011). Taken together,
this is suggestive evidence that systematic exposuremay be particularly
effective for improving gastrointestinal symptoms anddaily functioning
in individuals with IBS.
Somewhat surprisingly, improvements to daily functioning were
slightly but signiﬁcantly larger for interventions delivered online com-
pared to those delivered in-person. This could be good news for efforts
to enhance dissemination of treatment. However, only two online trials
were available for this analysis, and both were trials of CBT with expo-
sure, whichmay account for this effect (as noted previously, systematic
exposure may more directly increase daily functioning compared to
other therapeutic modalities). In addition to therapy type, there are
likely individual characteristics such as computer literacy that may in-
ﬂuence the efﬁcacy of online trials. Thiswill be important to assess in fu-
ture work.
We foundno signiﬁcant effect of therapy format (group vs. individual)
on effect size for either mental health or daily functioning. Our results
suggest that a group format may be an effective and economical method
of delivering psychological therapies to adults with IBS. As no trial to our
knowledge has investigated the efﬁcacy of CBT with exposure for IBS in a
group setting, this could be a fruitful area for future research.
Meta-regression analyses revealed no signiﬁcant effect of number of
therapy sessions on effect size for eithermental health or daily function-
ing. This ﬁnding, although in contrast to the implicit assumption that
more is “better”, is consistent with our recent ﬁnding that greater num-
ber of sessions did not predict greater improvements to gastrointestinal
symptoms (Laird et al., 2016). Our results indicate that the type of ther-
apy likely has a greater impact on outcomes than the number of talk
therapy sessions received. Surprisingly, greater session frequency was
151K.T. Laird et al. / Clinical Psychology Review 51 (2017) 142–152associated with smaller improvements to daily functioning in our sam-
ple of eligible trials. This result is in contrast to ﬁndings from a recent
meta-analysis of the efﬁcacy of psychotherapy for depression
(Cuijpers et al., 2013), in which greater session frequency was associat-
ed with greater improvement in depressive symptoms. When we re-
moved the trial with the highest session frequency from this analysis,
this result was no longer signiﬁcant. Thus, this ﬁnding should be
interpreted cautiously. Future trials are needed to explore the effect of
therapy session frequency on intervention efﬁcacy.
A strength of this systematic review and meta-analysis is our use of
rigorous methodology. Unlike prior meta-analyses in this ﬁeld, we in-
cluded a search of the “gray” literature. Also, two authors independently
assessed eligibility and performed the data extraction, and ITT data
were used wherever possible. Authors of potentially eligible studies
were contacted to obtain unreporteddata or to exclude ineligible partic-
ipants. This inclusive approach allowed us to analyze data from 31 trials
providing outcome data for 1747 individuals (861 of whom were
assigned to psychotherapy and 886 of whomwere assigned to an active
or non-active control). Eighteen of these trials provided data on daily
functioning, which to our knowledge is an outcome that no previous
meta-analysis of psychotherapy for IBS has evaluated.
Nonetheless, there are several limitations of the current study that
should be acknowledged. First, there was variability between trials
that could not be entirely explained by the trial characteristics exam-
ined in the moderator analyses. Although we collected data on a large
number of characteristics associated with the trial quality, interven-
tions, and participants, there still was residual heterogeneity across
the trials that was not explained by these characteristics. Future re-
search is needed to identify the contexts and clients for whom psycho-
therapy for IBS may be most or least effective.
A second limitation is that no trials included in the meta-analysis
were rated as having a low risk of bias in every domain assessed in
the risk of bias tool. This was in part due to the consistently high risk
of bias related to lack of blinding of participants and personnel, a risk
that is pervasive in psychological trials. However, even after excluding
this speciﬁc risk of bias domain, only nine trials included in the meta-
analysis were rated as low risk of bias in all remaining domains. Future
studies should follow the CONSORT guidelines for reporting random-
ized controlled trials (Schulz et al., 2010), use ITT designs, use active
control conditions to control for nonspeciﬁc treatment effects, and as-
sess treatment credibility and expectancy.
A third limitation derives from the inconsistent reporting of partici-
pants' demographic information (e.g., race, SES, duration of symptoms)
in the included trials, which precluded our ability to systematically ex-
plore variability in efﬁcacy across different populations. With better
reporting of demographic characteristics, including consistent reporting
of results by demographic subgroups, future meta-analyses will be able
to investigate whether there are individual characteristics that increase
the efﬁcacy of certain psychotherapy types or of psychotherapy in
general.
A ﬁnal limitation is that the majority of studies used interventions
that combined several different treatmentmodalities, making it difﬁcult
to sort studies into discrete categories. Furthermore, studies did not al-
ways provide sufﬁcient details regarding the components of their inter-
vention and the method in which it was delivered. To investigate the
components of psychotherapies that are most effective at alleviating
symptoms and improving daily functioning in IBS, clearer reporting of
treatment protocols is needed in the primary research literature.
Due to the limited number of trials, it was impossible in the current
analysis to investigate whether certain CBTs are more effective than
others. For example, only two trials of mindfulness-based therapy (a
third-wave CBT) for IBS were identiﬁed (Gaylord et al., 2011; Zernicke
et al., 2013). A third trial incorporated mindfulness skills into a more
traditional CBT protocol (Ljótsson et al., 2010). A meta-analysis of ac-
ceptance-based therapies for treatment of chronic pain (i.e., mindful-
ness-based stress reduction and acceptance and commitment therapy)found that these interventions had a signiﬁcant effect on reducing
pain (SMD = 0.25) (Veehof et al., 2011). The magnitude of this effect
was similar to the effect of CBT for reducing chronic pain (SMD = 0.21
compared to non-active control groups) (Williams et al., 2012). Because
so fewmindfulness-based therapies for IBS were identiﬁed in the current
meta-analysis, wewere unable to compare the efﬁcacy of these therapies
compared to other forms of CBT. Further research is needed in this area.
Mental health and daily functioning were assessed less frequently
than gastrointestinal symptoms in our sample of eligible RCTs of psy-
chotherapy for IBS. In particular, we located only 18 trials assessing
daily functioning, compared to the 41 RCTs that assessed gastrointesti-
nal symptoms (Laird et al., 2016). We believe that daily functioning is
an important outcome for investigation, as some adults with IBS experi-
ence profound impairment to daily activities. Assessment of functioning
allows for the differentiation between individuals who experience fre-
quent gastrointestinal symptoms but little or no functional limitations
versus those with signiﬁcant work, social, and activity limitations. Fu-
ture trials should consistently assess daily functioning using a measure
with good psychometric properties, such as the complete SF-36 or the
4-item Role Physical scale that assesses role limitations due to physical
health (the most commonly reported measure of daily functioning in
our eligible sample of trials) (Ware & Sherbourne, 1992).
Future work should continue to consider the mechanisms by which
psychotherapy for IBS improves physical symptoms, mental health, and
daily functioning, as this will provide insight into the processes that
should be targeted through treatment. Careful dismantling studies and
longitudinal assessment of hypothesized mediators will facilitate the
development of more effective and efﬁcient treatments for improving
gastrointestinal symptoms, mental health, and daily functioning in IBS.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cpr.2016.11.001.
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